Revelation Biosciences (REVB) Stock: Buy, Sell, or Hold?
REVB - Revelation Biosciences, Inc. Common Stock
$3.60
-0.15 (-4.00%)
▼
5d:
+400.21%
30d:
+267.35%
90d:
+236.45%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When REVB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: REVB is 271.1% above its trading range ($0.97). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: REVB is 271.1% above its trading range ($0.97). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: REVB is currently trading at $3.60, which is considered oversold relative to its 30-day fair value range of $0.74 to $0.97.
Technical Outlook: Technically, REVB is showing sideways momentum. Immediate support is located at $0.44, while resistance sits at $4.06. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: REVB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $124.25 (+3351.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, REVB is showing sideways momentum. Immediate support is located at $0.44, while resistance sits at $4.06. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: REVB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $124.25 (+3351.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.74 -
$0.97
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 3351.4% below Wall St target ($124.25)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.74 -
$0.97
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.44
Resistance Level
$4.06
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.18
Wall Street Target
$124.25
(+3351.4%)
Share & Embed Analysis
Last updated: October 22, 2026 9:36 AM ET
Data refreshes hourly during market hours. Next update: 10:36 AM
Data refreshes hourly during market hours. Next update: 10:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REVB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 60 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
15 analysts |
$52 | 62 BUY |
